程序性细胞死亡蛋白1及其配体通路在特发性炎症性肌病中的研究进展  

Programmed death-1/programmed death ligand-1 signaling pathway in idiopathic inflammatory myopathies

作　　者：施雁庭 黎皓[2] 郑捷[1] 曹华[1] Shih Yanting;Li Hao;Zheng Jie;Cao Hua(Department of Dermatology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China;Department of Oncology,Ruijin Hospital,Shanghai Jiao Tong University School of Medicine,Shanghai 200025,China)

机构地区：[1]上海交通大学医学院附属瑞金医院皮肤科,上海200025 [2]上海交通大学医学院附属瑞金医院肿瘤科,上海200025

出　　处：《中华皮肤科杂志》2022年第7期633-636,共4页Chinese Journal of Dermatology

基　　金：国家自然科学基金(81573037、81872523);国家临床重点专科建设项目(2012649);上海市科委医学引导类项目(134119a6100);上海申康医院发展中心临床创新三年行动计划(16CR3084B);上海交通大学医学院高峰学科--临床医学研究型医师(20172009);上海市"医苑新星"杰出青年医学人才培养资助计划(2019)。

摘　　要：程序性细胞死亡蛋白(PD-1)与其配体(PD-L1)特异性结合后,具有共抑制/共刺激的免疫调控作用,可抑制T细胞活化、增殖及细胞因子分泌,参与肿瘤免疫、自身免疫及免疫耐受等。本文综述PD-1/PD-L1信号通路的组成结构、调控机制,以助于理解特发性炎症性肌病合并恶性肿瘤的免疫机制,寻找潜在的治疗靶点和诊断策略。After the specific binding of programmed death-1(PD-1)to programmed death ligand 1(PD-L1),the PD-1/PD-L1 complex can exert a co-suppressive/co-stimulatory immunoregulatory effect,which can inhibit the activation and proliferation of T cells and their cytokine secretion,and play a key role in tumor immunity,autoimmunity and immune tolerance.This review summarizes structures and regulatory mechanisms of the PD-1/PD-L1 signaling pathway,aimming to facilitate the understanding of immune pathogenesis of idiopathic inflammatory myopathies complicated by malignant tumors,and to seek potential therapeutic targets and diagnostic strategies.

关 键 词：程序性细胞死亡受体1 肌炎 肿瘤 免疫检查点抑制剂 抗转录中介因子1-γ抗体 

分 类 号：R593.2[医药卫生—内科学]